RE:RE:RE:RE:RE:More colour on this very positive acquisitionHi, Digitel. The absence of financial details does make one pause. However, I'm not as concerned about dilution as some others seem to be. If the market responds positively to the Apicore acquisition and the new generic, our sp could conceivably be in the $10 range within, say, the next 6 months. A share issuance at that price - 4 millions shares? - would assuage many of your concerns, no? Plus, this stock would benefit from the added liquidity and better opportunities for institutional participation. Sure, the dilution would be significant, but isn't providing access to capital is the primary function of stock markets?
Also, given your concerns about the cost of the Apicore deal, I'm quite interested in hearing what you would have liked to see as a more reasonable approach.
Thanks to all, by the way, for your thoughtful contributions to this board.